The clinical research industry has experienced a seismic shift over the past few years, from the pandemic to decentralised trials to technological innovations.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh